Cholesterol drug may boost cancer therapy in genetic subtype
NCT ID NCT07213557
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests whether adding simvastatin, a common cholesterol medication, to standard chemotherapy and immunotherapy can help people with a specific genetic type of advanced stomach or esophagus cancer. About 84 adults whose cancer has a mutation in the ARID1A gene will receive either the standard treatment plus simvastatin or standard treatment alone. The goal is to see if the combination slows cancer growth longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC GASTROOESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori Fondazione G. Pascale
RECRUITINGNaples, Italia, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.